COMPARATIVE PHARMACOECONOMIC ANALYSIS OF THE APPLICATION OF POSACONAZOLE, FLUCONAZOLE AND ITRACONAZOLE WITH THE PURPOSE OF PRIMARY PREVENTION OF INVASIVE FUNGAL INFECTION IN PATIENTS WITH NEUTROPENIA DURING CHEMOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA OR MYELODYSPLASTIC SYNDROME

被引：0
|
作者：
Krysanov, I [1 ]
Krysanova, V [2 ]
机构：
[1] Moscow Natl Univ Food Prod, Postgrad Med Inst, Moscow, Russia
[2] IM Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1691
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY61
引用
收藏
页码：A532 / A532
页数：1
相关论文
共 37 条
  • [31] CD4+T-Cell Subsets in Aplastic Anemia, Myelodysplastic Syndrome, and Acute Myelogenous Leukemia Patients: a Comparative Analysis
    Feng, Xiumei
    Xu, Hongzhi
    Yin, Linlin
    Yin, Dongmei
    Jiang, Yang
    CLINICAL LABORATORY, 2023, 69 (07) : 1477 - 1483
  • [32] Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants
    Mauskopf, Josephine
    Chirila, Costel
    Graham, Jon
    Gersten, Iris D.
    Leather, Helen
    Maziarz, Richard T.
    Baden, Lindsey R.
    Bolanos-Meade, Javier
    Brown, Janice M. Y.
    Walsh, Thomas J.
    Horowitz, Mary H.
    Kurtzberg, Joanne
    Marr, Kieren A.
    Wingard, John R.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (17) : 1518 - 1527
  • [33] QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia
    Barreto, Jason N.
    Cullen, Michael W.
    Mara, Kristin C.
    Grove, Meagan E.
    Sierzchulski, Amanda G.
    Dahl, Nathan J.
    Tosh, Pritish K.
    Dierkhising, Ross A.
    Patnaik, Mrinal M.
    Ackerman, Michael J.
    LEUKEMIA & LYMPHOMA, 2019, 60 (14) : 3512 - 3520
  • [34] Therapeutic Drug Monitoring of Posaconazole in Adult Acute Myeloid Leukemia (Aml) Patients Receiving Posaconazole Prophylaxis during Induction: Experience from a Center with High Invasive Fungal Infection (IFI) Burden
    Sengar, Manju
    Dsouza, Sanyo
    Deshpande, Raviraj
    Jain, Hasmukh
    Gurjar, Murari
    Kannan, Sadhana
    Morajkar, Nayana
    Gota, Vikram
    BLOOD, 2016, 128 (22)
  • [35] Intravenous voriconazole (IV-VORI) prevents invasive fungal infections (IFI) in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Mattiuzzi, GN
    Alvarado, G
    Kantarjian, HM
    Verstovsek, S
    Cabanillas, M
    Faderl, S
    Lim, JT
    Giles, F
    Beran, M
    O'Brien, S
    Estey, EH
    BLOOD, 2004, 104 (11) : 253A - 253A
  • [36] Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations
    Cho, Sung-Yeon
    Lee, Dong-Gun
    Choi, Su-Mi
    Choi, Jae-Ki
    Lee, Hyo-Jin
    Kim, Si-Hyun
    Park, Sun Hee
    Choi, Jung-Hyun
    Yoo, Jin-Hong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Min, Woo-Sung
    MYCOSES, 2015, 58 (09) : 565 - 571
  • [37] Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation
    Liebenstein, Tyler K.
    Widmer, Kristin M.
    Fallon, Michael J.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (08) : 599 - 603
1234